Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS

Drugs of Today

Volumn 44, Issue 8, 2008, Pages 601-613

  Zivadinov, Robert ^a,b   Munschauer, Frederick E ^b   Ramanathan, Murali ^c   Benedict, Ralph H B ^b   Weinstock Guttman, Bianca ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b JACOBS NEUROLOGICAL INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; IBUPROFEN; INTERFERON BETA SERINE; PARACETAMOL;

ANTIINFLAMMATORY ACTIVITY; ASTHENIA; CHILL; COGNITION; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEVER; FLU LIKE SYNDROME; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; MULTIPLE SCLEROSIS; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIMAL DRUG DOSE; REVIEW; SIDE EFFECT;

ANIMALS; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 56049095072     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.8.1242250     Document Type: Review

References (93)

1. Sospedra, M., Martin, R. Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23: 683-747.
2. Fisher, E., Rudick, R.A., Simon, J.H. et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002, 59(9): 1412-20.
3. Hardmeier, M., Wagenpfeil, S., Freitag, P. et al. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 2005, 64(2): 236-40.
4. Jacobs, L.D., Cookfair, D.L., Rudick, R.A. et al. Intramuscular Interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996, 39(3): 285-94.
5. Lucchinetti, C., Brück, W., Parisi, J., Scheithauer, B., Rodriguez, M., Lassmann, H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000, 47(6): 707-17.
6. Lassmann, H., Brück, W., Lucchinetti, C.F. The immunopathology of multiple sclerosis: An overview. Brain Pathol 2007, 17(2): 210-18.
7. Ando, D.G., Clayton, J., Kono, D., Urban, J.L., Sercarz, E.E. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol 1989, 124(1): 132-43.
8. Viglietta, V., Baecher-Allan, C., Weiner, H.L., Hafler, D.A. Loss of functional suppression by CD4+ CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004, 199(7): 971-9.
9. Balashov, K.E., Khoury, S.J., Hafler, D.A., Weiner, H.L. Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. J Clin Invest 1995, 95(6): 2711-9.
10. Weinstock-Guttman, B., Ransohoff, R.M., Kinkel, R.P., Rudick, R.A. The interferons: Biological effects, mechanisms of actions, and use in multiple sclerosis. Ann Neurol 1995, 37(1): 7-15.
11. Calabresi, P.A., Pelfrey, C.M., Tranquill, L.R., Maloni, H., McFarland, H.F. VLA4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997, 49(4): 1111-6.
12. Zang, Y.C., Halder, J.B., Samanta, A.K., Hong, J., Rivera, V.M., Zhang, J.Z. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1α by interferon-beta. J Neuroimmunol 2001, 112(1-2): 174-80.
13. Stüve, O., Doodley, N.P., Uhm, J.H., Antel, J.P., Francis, G.S., Williams, G., Yong, V.W. Interferon beta 1b decreases migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9. Ann Neural 1996, 40(6): 853-63.
14. Boz, C., Ozmenoglu, M., Velioglu, S., Kilinc, K., Orem, A., Alioglu, Z., Altunayoglu, V. Matrix metallo-proteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin Neurol Neurosurg 2006, 108(2): 124-8.
15. Dressel, A., Mirowska-Guzel, D., Gerlach, C., Weber, F. Migration of T-cell subsets in multiple sclerosis and the effect of interferon-beta 1a. Acta Neurol Scand 2007, 116(3): 164-8.
16. Pozzilli, C., Bastianello, S., Koudriavtseva, T. et al. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: A short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996, 61 (3): 251-8.
17. Kraus, J., Oschmann, P. The impact of interferon-beta treatment on the blood-brain barrier. Drug Discov Today 2006, 11(15/16): 755-62.
18. Floris, S., Ruuls, S.R., Wierinckx, A. et al. Interferon-beta directly influences monocyte infiltration into the central nervous system. J Neuroimmunol 2002, 127(1-2): 69-79.
19. Prat, A., Biernacki, K., Antel, J.P. Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon beta and copolymer-1. J Autoimmun 2005, 24(2): 119-24.
20. Kraus, J., Ling, A.K., Hamm, S., Voigt, K., Oschmann, P., Engelhardt, B. Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro. Ann Neurol 2004, 56(2): 192-205.
21. Kuruganti, P.A., Hinojoza, J.R., Eaton, M.J., Ehmann, U.K., Sobel, R.A. Interferon-beta counteracts inflammatory mediator-induced effects on brain endothelial cell tight junction molecules-implications for multiple sclerosis. J Neuropathol Exp Neurol 2002, 61 (8): 710-24.
22. Harzheim, M., Stepien-Mering, M., Schroder, R., Schmidt, S. The expression of microfilament-associated cell-cell contacts in brain endothelial cells is modified by IFN-beta1a (Rebif®). J Interferon Cytokine Res 2004, 24(12): 711-6.
23. Byrnes, A.A., McArthur, J.C., Karp, C.L. Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neurol 2002, 51(2): 165-74.
24. Koike, F., Satoh, J., Miyake, S. et al. Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis. J Neuroimmunol 2003, 139(1-2): 109-18.
25. Kozovska, M.E., Hong, J., Zang, Y.C., Li, S., Rivera, V.M., Killian, J.M., Zhang, J.Z. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 1999, 53(8): 1692-7.
26. Rudick, R.A., Ransohoff, R.M., Lee, J.C., Peppler, R., Yu, M., Mathisen, P.M., Tuohy, V.K. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998, 50(5): 1294-300.
27. Wandinger, K.P., Sturzebecher, C.S., Bielekova, B. et al. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 2001, 50(3): 349-57.
28. Gigli, G., Caielli, S., Cutuli, D., Falcone, M. Innate immunity modulates autoimmunity: Type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation. Immunology 2007, 122(3): 409-17.
29. Brex, P.A., Ciccarelli, O., O'Riordan, J.I., Sailer M., Thompson, A.J., Miller, D.H. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002, 346(3): 158-64.
30. Lublin, F.D., Reingold, S.C. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46(4): 907-11.
31. Weinshenker, B.G., Bass, B., Rice, G.P., Noseworthy, J., Carriere, W., Baskerville, J., Ebers, G.C. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain 1989, 112(Pt. 1): 133-46.
32. National Multiple Sclerosis Society. Sourcebook: Progressive Disease. Available at: http://www. nationalmssociety.org/site/Page_Server?pagename= HOM_LIB_sourcebook_progressivems. Accessed December 21, 2007.
33. Confavreux, C., Vukusic, S., Adeleine, P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain 2003, 126(Pt. 4): 770-82.
34. Tomassini, V., Paolillo, A., Russo, P. et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006, 253(3): 287-93.
35. Tintoré, M., Rovira, A., Rio, J. et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006, 67(6): 968-72.
36. Dalton, C.M., Brex, P.A., Jenkins, R. et al. Progressive ventricular enlargement in patients presenting with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002, 73(2): 141-7.
37. Tekok-Kilic, A., Benedict, R.H., Zivadinov, R. Update on the relationships between neuropsychological dysfunction and structural MRI in multiple sclerosis. Expert Rev Neurother 2006, 6(3): 323-31.
38. Benedict, R.H., Zivadinov, R. Predicting neuropsychological abnormalities in multiple sclerosis. J Neurol Sci 2006, 245(1-2): 67-72.
39. Benedict, R.H., Bruce, J.M., Dwyer, M.G. et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol 2006, 63(9): 1301-6.
40. Kuhlmann, T., Lingfeld, G., Bitsch, A., Schuchardt, J., Bruck, W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002, 125(Pt. 10): 2202-12.
41. Trapp, B.D., Ransohoff, R.M., Fisher, E., Rudick, R.A. Neurodegeneration in multiple sclerosis: Relationship to neurological disability. Neuroscientist 1999, 5(1): 48-57.
42. O'Connor, P. The effects of intramuscular interferon beta-la in patients at high risk for development of multiple sclerosis: A post hoc analysis of data from CHAMPS. Clin Ther 2003, 25(11): 2865-74.
43. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001, 56(12): 1628-36.
44. Kinkel, R.P., Kollman, C., O'Connor, P. et al.; CHAMPIONS Study Group. IM Interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006, 66(5): 678-84.
45. Jacobs, L.D., Beck, R.W., Simon, J.H. et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclero sis. CHAMPS Study Group. N Engl J Med 2000, 343(13): 898-904.
46. Cohen, J.A., Cutter, G.R., Fischer, J.S. et al.; IMPACT Investigators. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002, 59(5): 679-87.
47. Clanet, M., Radue, E.W., Kappos, L. et al.; European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002, 59(10): 1507-17.
48. Clanet, M., Kappos, L., Hartung, H.-P., Hohlfeld, R.; European IFNbeta-1a Dose-Comparison Study Investigators. Interferon beta-1a in relapsing multiple sclerosis: Four-year extension of the European IFNbeta-1a Dose-Comparison Study. Mult Scler 2004, 10(2): 139-44.
49. Galetta, S.L., Markowitz, C., Lee, A.G. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: A systematic review. Arch Intern Med 2002, 162(19): 2161-9.
50. Simon, J.H., Jacobs, L.D., Campion, M. et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998, 43(1): 79-87.
51. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998, 352(9139): 1498-504.
52. Kirzinger, S.S., Arnason, B.G., Bigley, G.K. First phase of the BEYOND programme: Analysis of 3-year data from an open-label, extension study comparing 500 mcg and 250 mcg interferon beta-1b. 23rd Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (Oct 11-14, Prague) 2007, Abst P181.
53. Panitch, H., Goodin, D.S., Francis, G. et al., EVIDENCE Study Group and the University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS. The EVIDENCE trial. Neurology 2002, 59(10): 1496-506.
54. Durelli, L., Verdun, E., Barbero, P. et al.; Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1 a for multiple sclerosis: Results of a 2-year prospective randomised multi-centre study (INCOMIN). Lancet 2002, 359(9316): 1453-60.
55. Patti, F., Pappalardo, A., Florio, C., Politi, G., Fiorilla, T., Reggio, E., Reggio, A. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. Acta Neurol Scand 2006, 113(4): 241-7.
56. Paolillo, A., Pozzilli, C., Giugni, E. et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with interferon-beta. Eur J Neurol 2002, 9(6): 645-55.
57. Koch-Henriksen, N., Sørensen, P.S., Christensen, T. et al. Danish Multiple Sclerosis Group. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006, 66(7): 1056-60.
58. Limmroth, V., Malessa, R., Zettl, U.K. et al.; QUASIMS Study Group. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): A comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol 2007, 254(1): 67-77.
59. Benson, K., Hartz, A.J. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000, 342(25): 1878-86.
60. Baseline MRI characteristics of patients at high risk for multiple sclerosis: Results from the CHAMPS trial. Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study. Mult Scler 2002, 8(4): 330-8.
61. Predictors of short-term disease activity following a first clinical demyelinating event: Analysis of the CHAMPS placebo group. Mult Scler 2002, 8(5): 405-9.
62. CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 2002, 59(7): 998-1005.
63. Kinkel, R.P., O'Connor, P.W., Kremenchutzky, M. CHAMPS study reanalysis based on new clinically isolated syndrome classification criteria. Neurology [59th Annu Meet Am Acad Neurol (AAN) (Apr 28-May 4, Boston) 2007] 2007, 68(12, Suppl. 1): Abst.
64. Leary, S.M., Miller, D.H., Stevenson, V.L., Brex, P.A., Chard, D.T., Thompson, A.J. Interferon beta-1a in primary progressive MS: An exploratory, randomized, controlled trial. Neurology 2003, 60(1): 44-51.
65. Rudick, R.A., Cutter, G.R., Baier, M. et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult Scler 2005, 11(6): 626-34.
66. Rudick, R.A., Lee, J.C., Zhang, H. et al. Progression of disability at 2 years predicts disability at 8 years in relapsing MS: Analysis from the phase 3 clinical trial of intramuscular interferon beta-1a. 23rd Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (Oct 11-14, Prague) 2007, Abst P195.
67. Fischer, J.S., Priore, R.L., Jacobs, L.D., et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000, 48(6): 885-92.
68. Sabaté, E. (Ed.). Adherence to Long-Term Therapies: Evidence for Action. World Health Organization (Geneva) 2003.
69. Avonex® (interferon beta-1a) package insert. Biogen Idec, Inc., Cambridge, MA 2006.
70. Treadaway, K., Hawker, K., Racke, M. et al. Factors that influence compliance with disease-modifying therapy in multiple sclerosis. 21st Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (Sept 28-Oct 1, Thessaloniki) 2005, Abst.
71. Devonshire, V., Lapierre, Y., Macdonell, R. et al. The Global Adherence Project - a multicentre observational study on adherence to disease-modifying therapies in patients suffering from relapsing-remitting multiple sclerosis. Multiple Scler [22nd Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (Sept 27-30, Madrid) 2006] 2006, 12(1, Suppl.): Abst P316.
72. Phillips, J.T., Weinstock-Guttman, B; Avonex® Autoinjector Study Group. Assessing patient satisfaction with an autoinjector for intramuscular IFN beta-1a (Avonex®). 21st Ann Meet Consortium Multiple Scler Centers (CMSC) (May 30-June 2, Washington, D.C.) 2007, Abst.
73. Van Walderveen, M.A., Kamphorst, W., Scheltens, P. et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998, 50(5): 1282-8.
74. Simon, J.H. Brain atrophy in multiple sclerosis: What we know and would like to know. Mult Scler 2006, 12(6): 679-87.
75. Zivadinov, R., Sepcic, J., Nasuelli, D. et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001, 70(6): 773-80.
76. Chard, D.T., Griffin, C.M., Parker, G.J.M., Kapoor, R., Thompson, A.J., Miller, D.H. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002, 125(Pt, 2): 327-37.
77. Sastre-Garriga, J., Ingle, G.T., Chard, D.T., Cercignani, M., Ramió-Torrentà, L., Miller, D.H., Thompson, A.J. Grey and white matter volume changes in early primary progressive multiple sclerosis: A longitudinal study. Brain 2005, 128(Pt. 6): 1454-60.
78. Chard, D.T., Griffin, C.M., Rashid, W. et al. Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis. Mult Scler 2004, 10(4): 387-91.
79. Horakova, D., Cox, J.L., Havrdova, E. et al. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years. A case control study. J Neurol Neurosurg Psychiatry 2008, 79(4): 407-14.
80. Rudick, R.A., Fisher, E., Lee, J.-C., Simon, J., Jacobs, L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999, 53(8): 1698-1704.
81. Filippi, M., Bozzali, M., Rovaris, M. et al. Evidence for widespread axonal damage at the earliest stage of multiple sclerosis. Brain 2003, 126(Pt. 2): 433-7.
82. Iannucci, G., Tortorella, C., Rovaris, M., Sormani, M.P., Comi, G., Filippi, M. Prognostic value of MR and magnetization transfer imaging findings in pa-tients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR Am J Neuroradiol 2000, 21(6): 1034-8.
83. Simon, J.H., Lull, J., Jacobs, L.D. et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 2000, 55(2): 185-92.
84. Radue, E.-W., Sahraian, M.A., Hallerfrom, S. et al. The evaluation of black hole volume evolution as it relates to lesion load, extent of enhancement, and treatment with intramuscular interferon beta-1a in 2 relapsing-remitting multiple sclerosis studies. Multiple Scler [22nd Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (Sept 27-30, Madrid) 2006] 2006, 12(1, Suppl.): Abst.
85. Zivadinov, R., Locatelli, L., Cookfair, D. et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler 2007, 13(4): 490-501.
86. Filippi, M., Rovaris, M., Inglese, M., Barkhof, F., De Stefano, N., Smith, S., Comi, G. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: A randomized, double-blind, placebo-controlled trial. Lancet 2004, 364(9444): 1489-96.
87. Kita, M., Goodkin, D.E., Bacchetti, P., Waubant, E., Nelson, S.J., Majumdar, S. Magnetization transfer ratio in new MS lesions before and during therapy with IFN beta-1a. Neurology 2000, 54(9): 1741-5.
88. Zivadinov, R., Cookfair, D., Munschauer, F.E. et al. Effect of interferon beta-1a on changes of non-conventional MRI measures in patients with multiple sclerosis. Multiple Scler [22nd Congr Eur Comm Treat Res Multiple Scler (ECTRIMS) (Sept 27-30, Madrid) 2006] 2006, 12(1, Suppl.): Abst P700.
89. Brandes, D.W., Bigley, K., Hornstein, W., Cohen, H., Au, W., Shuin, R. Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: A pilot study. Curr Med Res Opin 2007, 23(7): 1667-72.
90. Herndon, R.M., Rudick, R.A., Munschauer, F.E. et al. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler 2005, 11(4): 409-19.
91. Santos, R., Weinstock-Guttman, B., Tamaño-Blanco, M. et al. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. J Neuroimmunol 2006, 176(1-2): 125-33.
92. Bertolotto, A., Malucchi, S., Sala, A. et al. Differential effects of three interferon betas on neutralising anti-bodies in patients with multiple sclerosis: A follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002, 73(2): 148-53.
93. Dhib-Jalbut, S., Arnold, D.L., Cleveland, D.W. et al. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol 2006, 176(1-2): 198-215.